Researchers Evaluate Combination Rabies/Ebola Vaccine in Primates

Visit us on the Web Follow us on Twitter Visit us on Facebook Follow us on LinkedIn Researchers Evaluate Combination Rabies/Ebola Vaccine in Primates Ebola virus, a deadly infection first reported in 1976, causes severe hemorrhagic fever – including bleeding, organ failure, and death – in people and nonhuman primates. Continuing outbreaks of Ebola and the virus’ potential for use as a bioterrorism agent have spurred research toward a safe and effective vaccine. To this end, researchers at NIAID and Thomas Jefferson University developed and recently evaluated a novel Ebola vaccine based on the existing rabies virus vaccine. The scientists tested three versions of the novel vaccine in nonhuman primates, and found that all three produced potent immune responses against both rabies and Ebola. Of those, one version protected 100 percent of primates against challenge with the Ebola virus. The researchers plan to pursue development of this vaccine for potential use in humans and wildlife. For more information on the study results and future steps, read the NIAID science update at: http://www.niaid.nih.gov/topics/ebolaMarburg/Pages/rabiesVaccEbola.aspx. Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@govdelivery.com. This service is provided to you at no charge by the National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to buzzhairs.health@blogger.com using GovDelivery, on behalf of: National Institute of Allergy and Infectious Diseases · 6610 Rockledge Drive · Bethesda, MD 20892 · 866-284-4107